BioCentury | Sep 3, 2020
Management Tracks

Dier joining Ultragenyx as CFO; plus Magenta, Galectin, Immunicum, BrainStorm, Vaccinex

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) hired Mardi Dier as EVP and CFO. She will succeed Shalini Sharp, who will remain CFO until the former CFO and CBO of Portola Pharmaceuticals Inc. starts Nov. 2. Stem cell therapy...
BioCentury | Aug 8, 2020
Management Tracks

PacBio shifts executive team; plus changes at CMAB, Valo, Alentis, Amwell and more

Pacific Biosciences of California Inc. (NASDAQ:PACB) announced a series of management changes Friday. Chairman Christian Henry will become president and CEO, effective Sept. 14. John Milligan, a member of the sequencing company’s board, will succeed...
BioCentury | Feb 22, 2020
Management Tracks

Everest names new CEO; plus Merck, Gilead, Turning Point, Adaptimmune, AskBio and more

Everest Medicines Ltd. hired Kerry Blanchard as CEO. Blanchard, who will also join the company’s board, succeeds interim CEO Sean Cao. Blanchard was an operating partner at Everest’s founding investor CBC Group and previously served...
BioCentury | Aug 23, 2019
Translation in Brief

New Therapeutic Targets and Biomarkers: July 2019

New Therapeutic Targets and Biomarkers: July 2019 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database in July. Therapeutic targets are defined as any protein, gene or other molecule...
BioCentury | Aug 21, 2019
Distillery Therapeutics

LGALS3 identified as Huntington disease target

DISEASE CATEGORY: Neurology INDICATION: Huntington disease (HD) Inhibiting the lectin LGALS3 could treat HD, which is caused by aggregation of mutant HTT. Plasma levels of LGALS3 protein were higher in 26 symptomatic HD patients than...
BioCentury | Jul 11, 2019
Distillery Therapeutics

Treating asthma, allergic diseases with mAbs against crystallized proteins

DISEASE CATEGORY: Inflammation INDICATION: Asthma argenx and VIB have developed antibodies against LGALS10 that could help treat asthma and other allergic airway diseases. Patients with severe asthma had crystals comprising LGALS10 in airway tissue and...
BioCentury | May 28, 2019
Financial News

May 28 Financial Quick Takes: Alphamab Oncology raises $60M; plus $180.5M for Panacea healthcare fund and more

Hudson Bay leads Alphamab Oncology's $60M series B Alphamab Oncology (Cayman) raised $60 million in a series B round led by Hudson Bay Capital, with participation from new investor and entrepreneur Adrian Cheng and existing...
BioCentury | May 24, 2019

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

It is clear that Europe has hotspots of innovation that are discovering and developing the next wave of new therapeutic modalities. Nearly every category of new modality has a European champion, with clusters forming around...
BioCentury | Mar 9, 2019

Seventure maps its microbiome future

Seventure Partners' second microbiome-based fund aims to foster a generation of companies beyond those focused only on live therapeutics. On March 5, the firm announced a first close of Health for Life Capital II, intended...
BioCentury | Mar 5, 2019
Financial News

First close for Seventure's new microbiome fund

Seventure Partners announced the first close of its second microbiome-focused health fund and is targeting a €200 million ($226.9 million) final raise. Seventure's Isabelle de Cremoux said the VC has raised more than half of...
Items per page:
1 - 10 of 166